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Summary Four Ugandan patients (1 women, 3 men) with generalized Kaposi's sarcoma (KS) were seen in
the Uganda Cancer Institute between October 1983 and December 1984. They presented with generalized
lymphadenopathy, plaques/nodules on the body, general swelling of the head, oral and visceral involvement
and respiratory distress. Initial responses to adriamycin as a single agent or a combination chemotherapy of
actinomycin D, vincristine, adriamycin and imidazole carboxamide appeared to be favourable but no
sustained response was obtained. Serological tests for human T-lymphotropic virus (HTLV-II) antibodies
were positive in all 4 cases.
Kaposi's sarcoma is the 7th commonest tumour in
Uganda with an annual incidence of about
0.7/100,000 in Kampala and is commoner in men
than women (M: F of 9:1). The common or
peripheral form of the disease usually starts with
swelling in the lower limbs followed by the
appearance of skin nodules or plaques. It is slowly
progressive and responds well to chemotherapy.
The disease may be locally aggressive and Taylor
further divided this form into infiltrative or florid
type. An alternative presentation classified by
Templeton as generalized type is also occasionally
seen. The various presentations of Kaposi's
sarcoma in Uganda have been described by several
authors (Kyalwazi, 1981; Taylor et al., 1971;
Olweny et-al., 1976; Lothe, 1963; Templeton, 1972).
An aggressive form of Kaposi's sarcoma has
recently been described in Zambian patients
(Bayley, 1984). The main clinical features are
disseminated disease often with no skin lesions,
generalized lymphadenopathy and a poor response
to conventional chemotherapy. This form of the
disease is clinically very similar to childhood KS
and to AIDS related KS in the USA (Levy &
Ziegler, 1983). In Zambia aggressive KS but not
endemic KS is associated with infection with
HTLV-III (Bayley, et al., 1985).
In Uganda during the period 1980-84 a total of
194 cases of KS in adult males were registered by
the Department of Pathology, of which 33 were
generalized. This report describes the clinical
features of three of these cases and of one female
with a view to establishing if this is the same
disease as aggressive KS in Zambia.
Patients and methods
All four patients were admitted to the Uganda
Cancer Institute between October 1983 and
December 1984 and had histologically proven
Kaposi's sarcoma from biopsies of palpable lymph
nodes and skin lesions when present. Pre-treatment
evaluation included a detailed clinical examination,
a complete blood count, examination of stool for
ova or cysts, chest radiograph, ECG and clinical
photograph. Blood samples were assayed for
antibodies to HTLV-III in the UK.
Patients were randomized to receive one of the
following regimens intravenously every 3 weeks
(Olweny, 1981; Olweny et al., 1974; Vogel et al.,
1973):
1. Adriamycin (ADM) 75mgm-2 as a single agent
or
2. Actinomycin-D (Act-D) 0.2mg m-2 for 5 days
and vincristine (VCR) 1.4mg m-2 day I and
5 +ADM 60 mgm-2 day 1+imidazole carbox-
amide (DTIC) 100 mg for 5 days.
Patient medical records in the Department of
Pathology were examined for the period 1980-1984
for the incidence of generalised Kaposi's sarcoma.
Antibodies to HTLV-III were tested by a
competitive ELIZA as previously described
(Cheingsong-Popov et al., 1984; Serwadda et al.,
1985). Essentially test serum and a preparation
of HTLV-III antibody-positive IgG coupled to
horseradish peroxidase (HRPO) were mixed
together in wells coated with a crude gamma
globulin preparation from an HTLV-IlI seropositive
patient. Antigen derived from a lysate of infected
cells was added and the mixture incubated at 45°C
for 1 h. The wells were then washed and adsorbed
HRPO assayed with tetramethyl benzidine in citrate
acetate buffer containing H202. A positive serum
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was taken as one which gave a 50% inhibition of
colour formation compared to an HTLV-III
antibody negative serum.
Case summaries
Case 1 A 26 year old female, presented in October 1983
with multiple nodular swelling on the head, face and body
and marked weight loss. She had been unwell for 8
months prior to admission with general weakness and
intermittent fever; no history of diarrhoea was given but
her appetite was poor. She was married with 2 children
and lived in South West Uganda. There was no history of
promiscuous behaviour, drug abuse or blood transfusion.
Physical examination of the patient revealed moderate
anaemia, gross general lymphadenopathy, moderate
wasting with few nodules on the head and trunk
(Figure 1) and none on the limbs. She had bilateral
enlarged tonsils, a pleural effusion (R) side, liver
enlargement 6cm below the costal margin and moderate
splenomegaly. She had a haemoglobin of 8.4gdl-1, WBC
of 4.2 x 109 1- (N; 63% L; 34% E; 1%) and was HTLV
III seropositive.
Figure 1
head.
Case number 1 showing nodules on the
A chest radiograph showed extensive infiltration of
both lung fields. A pleural biopsy was positive for
Kaposi's sarcoma (mixed cellularity). She was randomized
to receive Adriamycin as a single agent and after 3
courses of chemotherapy she had a clinical reduction in
tumour of 50%, including reduction in lymph node and
skin nodule size. Her weight increased by 10kg and the
chest radiograph returned almost to normal.
Disease remained fairly stable, until July 1984 when her
general condition had deteriorated, nodules on the head
had regrown, new plaques had appeared on the medial
aspect of the thigh with extensive infiltration to give a
tourniquet-like effect. She was very dyspnoeic and the
liver and spleen almost filled the abdomen. Chest
radiograph showed the (R) pleura full of fluid and some
fluid on the left. She developed progressive dyspnoeia and
congestive cardiac failure and eventually died, despite
chemotherapy, in November 1984. Post mortem
examination showed Kaposi's sarcoma involving the
tongue, tonsils, oesophagus, stomach and both large and
small gut. There were also tumour nodules in the liver,
spleen and intra-abdominal lymph nodes. In the chest
tumour nodules were seen on the pleura (parietal), lungs
and hilar lymph nodes. The diaphragm, pericardium and
left ventricle were also found to have tumour deposits.
Case 2 A 30 year old doctor was referred to Uganda
Cancer Institute with a clinical diagnosis of disseminated
Kaposi's sarcoma confirmed on histology as mixed
cellularity. He presented at a small district hospital 6
months prior to admission with facial puffiness,
generalised nodular skin lesions, general malaise, weight
loss and abdominal pain associated with diarrhoea. He
denied sexual promiscuity but had a steady sexual partner
who developed lymphadenopathy 6 months later. A single
child is apparently healthy. There was no history of blood
transfusion, drug abuse or homosexuality.
On arrival the following findings were noted: he was
very sick and had generalised oedema of the head and
nodular skin lesions. He was wasted and dyspnoeic. There
was a fungating purple mass in the oral cavity extending
from the soft palate. The tongue was coated with oral
thrush. There was generalised lymphadenopathy, bilateral
pleural effusion, a palpable spleen and a diffuse mass in
the right iliac fossa.
The cerebrospinal fluid was xanthochromic with a
protein concentration of >120mgdl-l and no organisms
were isolated. He had an Hb of 7.7gdl -1, WBC of
5.9 x 1091-l, (L; 31%, N; 66%, E; 3%). The stool contained
Shistosoma mansoni, and Strongyloides stercolatis and he
was HTLV III seropositive. A repeat biopsy of the lymph
node, pleura, oral and skin lesions all confirmed Kaposi's
sarcoma (mixed cellularity).
The patient was given six courses of four drug
combinations; Adriamycin, Vincristine, DTIC and
Actinomycin D. He continued to deteriorate with minimal
clinical response and died 6 months later with respiratory
failure. Autopsy was not done.
Case 3 A 44 year old depot manager from South West
Uganda, married with 4 children, presented in March 1984
with general lymphadenopathy, 1 month history of
diarrhoea (Novs et al., 1974) and weight loss. There was
no history of drug abuse, homosexual behaviour or blood
transfusion.
Examination revealed general ill health, wasting with
moderate anaemia, oral candidiasis, and enlarged tonsils
bilaterally. He had hepatomegaly 3cm below the sub-
costal margin mid-clavicular line but no skin nodules or
plaques.
Lymph node biopsy revealed mixed cellularity Kaposi's
sarcoma. WBC; 3.5 x 1091-1 (normal differential). He was
seropositive for HTLV-III. Despite ADM as a single
agent, he died with a massive pleural effusion and respira-
tory distress in May 1984. Autopsy was refused.
Case 4 A 19 year old fisherman from South West
Uganda married but with no children presented in
November 1984 with general swelling of the head
(Figure 2) prior to 1 month history of diarrhoea and
intermittent fever. There was no history of drug abuse,
homosexual behaviour or blood transfusion.
Physical examination was remarkable for the weight
loss, nodules on the tongue and enlarged tonsils, nodules
on the chest but none on the limbs; he had lympha-
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Figure 2 Case number 4 showing general swelling of
the head and nodules on the chest.
4 x l091- 1 (L; 26%, N; 68%, E; 6%). HTLV III
seropositive; histology of the lymph nodes showed
monomorphic KS. He was given Adriamycin as a single
agent with no response and died at home in February
1985.
From the pathology records a total of 194 cases of
Kaposi sarcoma were registered between 1980-1984 in
adult males of which 33 cases were generalized Kaposi
sarcoma (17%). (Table I).
From 1980-1983 the percentage of cases which were
generalized increased year by year until in 1983 it reached
31%. However in 1984 it fell back to 17.7%.
Table I Number of new cases of Kaposi's sarcoma in
adult males
1980 1981 1982 1983 1984 Total
Endemic KS 43 31 30 20 37 161
Generalized KS 3 3 10 9 8 33
(6.5%)(8.8%)(25%) (31%) (17.7%)
46 34 40 29 45 194
Discussion
The common or peripheral form of Kaposi sarcoma
has been classified as nodular and as locally
aggressive by Templeton (1972). Taylor et al. (1971)
further divided the locally aggressive form into
infiltrative and florid type. This common or
peripheral form is also described as endemic by
Bayley (1984), but however described this disease
presentation accounts for over 80% of cases in
Uganda.
The major distinguishing features of aggressive
disease as described by Bayley are: the absence of
skin lesions, a poor response to conventional
chemotherapy; its appearance in a younger
population; disseminated disease usually involving
lymph nodes; a poor prognosis and evidence of
infection with HTLV-III.
From October 1983-December 1984 we saw
four patients with generalized lymphadenopathy,
oral lesions and visceral involvement or general
swelling of the head. Cutaneous nodules/plaques on
the limbs were not seen. The patients were young
(average age 29.5 years; range 16-44 years) and the
duration of illness prior to admission was relatively
short (average 4 months; range 1-9 months); all the
patients are now dead. One died within 2 months of
admission with no response to chemotherapy, but
the other three had an initial response. The average
duration of survival from time of admission was 8
months (range 2-12 months). Histologically the
disease was of the mixed cellularity type except in
one case where monomorphic Kaposi's sarcoma
was seen in a lymph node which is unusual in our
experience and may indicate differences in the
underlying pathology. All 4 patients had antibodies
to HTLV-III. We conclude that the cases described
here fit Bayley's description of aggressive KS.
Bayley also reported that she was seeing an
increasing number of aggressive cases which
prompted us to review the histological request
forms at the Department of Pathology, Makerere
University, between January 1st 1980 and
December 1984. Overall 17% of the cases of KS in
adult males during that period had generalized
disease compared with only 3% in 1972
(Templeton, 1972) confirming an increased
incidence of this form of KS. However the year by
year increase seen from 1980-1983 was not
maintained in 1984. It would appear then that
generalized KS in the 4 Ugandan patients studied is
the same disease as aggressive KS in Zambia.
Overall the incidence of this form of KS has
increased substantially since 1972.
The fact that all 4 patients in this study had
generalised KS and were infected with HTLV-III
suggests they were suffering from AIDS. Indeed as
further evidence two of them had oral candidiasis,
an early marker of severe immunosuppression
(Roberts et al., 1984). It is tempting to extrapolate
from the present series of 4 patients to all cases of
generalized disease seen in Uganda over the past 10
years and say that the generalized presentation is
part of the AIDS spectrum. However this would be
unjustified and probably wrong. It seems likely that
KS can present as a generalized disease in response
to a number of different factors and infection with
a lymphotropic virus is only one of them. For
example KS in older men tends to become more
generalized even when the patient is not infected
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group where the disease is generalized but not
necessarily associated with HTLV-III (unpublished
observations). Nevertheless it is possible that a
proportion of the patients with generalized KS seen
in Kampala over the past 10 years, particularly
those in their early adulthood, did have AIDS. The
critical deciding factor is whether or not they were
infected with HTLV-III. Although we may never
know the answer to this question there is evidence
that the virus was present in Uganda in 1972
(Saxinger et al., 1985a,b). Sera collected in the
West Nile District from healthy children showed a
high prevalence (66%) of antibodies to HTLV-III
(or a related virus) by ELIZA, later confirmed by
western blotting. Furthermore recent serological
data (Serwadda et al., 1985) indicate that the virus
is endemic; 10% of the healthy adult population
who have no obvious risk factors are infected.
Taken together these findings suggest that the
origin of HTLV-III or a related virus in the
Ugandan population is not recent.
If the virus has been present in Uganda since
1972 one has to ask why AIDS was not reported
until this year (Serwadda et al., 1985), given that
disease surveillance has always been of a high
standard. One possible explanation is that part of
the population has immunity to the virus, perhaps
those infected in early childhood, and that the
current epidemic reflects escape by the virus to the
non-immune population.
An equally plausible explanation is that the virus
detected in 1972 is related to HTLV-III but is itself
non-pathogenic. Such a virus might have been the
predecessor from which the pathogenic AIDS virus
arose by mutation. Distinguishing between the
various alternatives is of vital importance to our
understanding of the pathogenicity and eventual
control of this virus.
We are indebted to Professor Bayley for reading the
manuscript, to M. Roff for technical assistance and to J.
Leese and G. Prentis for typing.
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